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While a growing body of research is uncovering the aetiology and effective treatments for allergy, research that
assess the broader ethical implications of this disease is lacking significantly. This article will demonstrate both the
paucity of academic research concerning ethical implications in allergy and explain why ethical analysis is integral
to formulating effective health strategies for allergic disease. An exhaustive literature search of publications in
French and English identified less than 35 academic articles focussed on the topic of ethics and allergy; this is a
miniscule number when compared to the amount of articles published on ethical issues related to other chronic
illnesses, such as obesity. It is important to demonstrate to allergy specialists the need for, and utility of, further
incorporating ethical analyses in allergology; the current success of Ethical, Legal, Social Implications (ELSI) research
programmes in human genetics and nanotechnology will serve as notable examples. Indeed, future research and
innovation in allergy will undoubtedly encounter ethical dilemmas and the allergology community should play a
significant role in helping to address these issues. However, incorporating ethical analyses in allergology does not
imply that the allergology community must acquire extensive knowledge in bioethics; instead, interdisciplinary
research that incorporates expertise from allergology and bioethics would enable allergy specialists to advance
critical knowledge development in this largely overlooked domain of study.
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Introduction
Without a doubt, the sudden development of an epi-
demic of a chronic disease would garner significant con-
cern amongst the public, clinicians and health officials. It
is reasonable to assume that such concern would then
motivate the conduct of empirical studies to identify the
underlying mechanisms of the disease in order to then
evaluate possible health interventions. With such know-
ledge, value-based judgements and thorough debate cen-
tring on how best to prioritize and disseminate treatment
options and preventive efforts would likely follow. Of
additional importance would be to investigate the
broader societal, ethical and legal implications (ELSI)
that an emerging epidemic will inevitably raise for soci-
ety. While logical, this sequence of events appears to be
less-than-ideal with regards to the treatment of allergy
and atopic conditions.
A seeming weakness in allergology is how the field
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reproduction in any medium, provided the orof treatment strategies, and the justification of value-
based judgements about particular health policies. Or
in other words, there is a considerable lack of ana-
lysis concerning the ethics and legitimacy of allergy
research initiatives, treatments, and health policies.
Consider, for example, the enactment of Sabrina’s
Law in Ontario, Canada in 2006 [1]. Following the
tragic death of student from an anaphylactic reaction
on school premises, the provincial government man-
dated that all public schools must “have policies or
procedures in place to address anaphylaxis in
schools, which includes providing instruction to staff
and guidance on the administration of medication”
[1]. Though being progressive legislation that marked
a significant step forward towards protecting the
health of allergic students, there is little evidence
that the ethical implications of this legislation was
investigated prior to its implementation. Indeed, eth-
ical assessments of food allergy policies for schools
only began four years after Sabrina’s Law became for-
mal legislation [2].
A recent editorial written by prominent researchers in
allergology and published in the journal Allergy helps tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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allergology into context [3]. This editorial provides an
overview of several global allergy research networks and
future research areas that are of foremost interest. Rather
surprisingly, only investigations centring on physiological
aspects of allergy were deemed of importance; no men-
tion is made of the need for future analyses that serve to
identify the broader social, legal, and ethical factors that
significantly influence allergy treatment strategies and
the population distribution of morbidity. The omission
of the latter should not be misconstrued to imply that
the broader and “less technocratic” social, legal and eth-
ical issues of allergy have been investigated in depth and
thus merit little, if any, priority.
Recent trends in health research suggest the contrary.
As demonstrated by developments from the Human
Genome Project throughout the 1990’s, leading geneti-
cists understood from the beginning that rapid develop-
ments in health technologies will raise “ethical, legal,
and social issues that [will] require careful attention by
scientists, health care professionals, government offi-
cials, and the public” [4], p. 291. Indeed, along with
greater knowledge of genetics, the ability to map
human genomes raised several ethical concerns; for ex-
ample, the emergence of novel means to discriminate
against individuals based on their genetic makeup [4].
Cognizant of these issues, an ELSI research programme
for human genetics was made an integral component of
the Human Genome Project. Promoting ELSI investiga-
tions thus served to identify possible risks that may
arise from genetic research, and correspondingly, de-
velop appropriate policies to circumvent these risks in
the future. In addition to emerging health technologies,
similar ELSI programmes have since been developed for
chronic diseases, such as the University of Pennsylva-
nia’s newly inaugurated Neurodegenerative Disease Eth-
ics and Policy Program [5]. This programme aims to
“support research, education and training to identify
and address the ethical and policy implications of
advances in the diagnosis and treatment of neurodegen-
erative diseases, and work toward forming best prac-
tices for how these advances can be successfully
translated into clinical practice” [5]. In light of the
growing recognition of the need for ELSI studies to be
integral components of health research initiatives, this
article will demonstrate that concerted ethical analysis
in allergology is arguably deficient, thus signifying that
research in this sub-specialisation in allergy scholarship
merits targeted development, and moreover, establish-
ment of ELSI programmes within allergology.
The proposals put forth, however, will not argue that
allergologists should now put aside their lab coats and
focus on philosophical debates concerning “how many
allergens can one fit on the head of a pin?”. Rather, theaim here is to further sensitize allergy specialists to the
range of social and political factors that influence clinical
practice and the implementation of research findings,
and the contexts in which such research raises import-
ant ethical issues. With greater awareness of such issues,
allergy specialists will be better positioned to engage in
interdisciplinary research with members of the bioethics
community in order to advance ethical analysis and de-
bate in allergology. More generally, interdisciplinary re-
search between these communities will help define the
values that ought to guide decisions in health policy and
public health interventions for allergy.
Scientific research and clinical experience serve to in-
form us of the underlying causes of disease, what the
risks and benefits are concerning known treatment strat-
egies, and whether emerging treatment modalities show
promise in further reducing morbidity. It is wrong, how-
ever, to assume that scientific investigation and clinical
practice in allergology – and the influence of both on
health policy – exist within a purely objective, value-free
space. Rather, all of these domains in health are inter-
linked and raise ethical questions in need of consider-
ation [6-8]. What are the goals of allergy research, and
how ought these goals define how resulting medical
innovation is implemented and distributed amongst the
population? Which forms of allergy morbidity are most
significant and, under inevitable conditions of limited
resources, which populations of allergy sufferers merit
priority in targeted health interventions? What constitu-
tes an effective treatment of atopic disorders, and what
proportion of treatment strategies ought to comprise dis-
ease prevention efforts? The above are but a brief list of
important ethical questions – with no simple answers –
that must be subjected to ethical reflection and analysis
in order to achieve a measure of consensus and recog-
nition of legitimacy, as well as to enable political action
(i.e., informed public policy). It is evident that the voice
of the allergology community is essential to these dis-
cussions, and in turn, will determine society’s success in
attenuating the devastating health consequences of the
expanding epidemic of allergy.
But first, this article will now demonstrate the current
(limited) extent of ethical analysis in allergologya.
Methodology
An exhaustive literature search was conducted during the
months of January to March 2012, via the Internet using
the following academic search engines and online data-
bases: GoogleScholar (www.googlescholar.com), PubMed
(www.ncbi.nlm.nih.gov/pubmed), Web of Knowledge
(Thompson Reuters; www.webofknowledge.com), CAIRN.
info (www.cairn.info), Érudit (www.erudit.org), and Refdoc.
fr (www.refdoc.fr). Manuscripts in the form of publications
in academic journals written in English or French were
Table 1 Manuscripts other than articles excluded from
the primary analysis
Year of publication Author(s) Of interest Reference
2011 Murphy, Sandel X [9]
Kling X [10]
2010 Kling X [11]
Wolf et al. [12]
Bleecker et al. [13]
Martinez, Fabbri [14]
Naspitz, Warner X [15]
2007 Payne [16]
Hourihane, Beirne X [17]
2006 Coffey, Ross [18]
2004 Kling X [19]
2002 Carter [20]





1999 Ferdman, Church [26]
1998 Kelso [27]
1995 Mansmann [28]
Eaton, Downing X [29]
Reisman [30]







Bold and italic font indicates a manuscript written in French.
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scripts appearing in academic journals or books (e.g., the-
ses, institutional newsletters, conference proceedings, news
articles) were excluded from the analysis.
An exhaustive search for ethics analyses concerning al-
lergic disease and common atopic disorders was con-
ducted using the keywords: ‘allergy’, ‘atopy’, ‘atopic’,
‘urticaria’, ‘rhinitis’, ‘dermatitis’, ‘anaphylaxis’, and ‘asthma’,
which were paired with ‘bioethics’, ‘ethics’, ‘ethical’, ‘moral’,
and ‘unethical’ to enable independent searches for each
possible pairing of terms (e.g., ‘asthma ethics’, ‘atopy
moral’, etc.). An equivalent search was repeated using
the same key words in French (uticaire, rhinite, derma-
tite, atopie, atopique, allergie, anaphylaxie; éthique,
bioéthique, morale, moraux). Manuscripts retrieved for
each pair of search terms were assessed for content and
inclusion in this study. Manuscripts were further
excluded from analysis if they met the following criteria:
1) ethics terminology was mentioned only in passing
(e.g., appear in two or fewer sentences) and the analyt-
ical content of the manuscript did not focus discussion
on ethical issues; 2) the manuscript only mentioned
ethics in relation to the research project having passed
ethical review by an Insitutional Review Board (e.g.,
IRB, ethics advisory board, protocols for the ethical con-
duct of human subjects in research, etc.); 3) provided
titles and abstracts in English or French but the text of
the manuscript is of another language. The remaining
manuscripts were read and further divided into two cat-
egories which determined their inclusion in the primary
analysis or whether they were merely listed in a separate
table in this article: 1) manuscripts of the category of aca-
demic articles are included in the primary analysis
(comprising research, review, debate/discussion pieces,
etc.); 2) manuscripts comprising shorter publications in
the form of correspondences, letters to the editor, brief
commentaries, and editorials are listed in Table 1 only
and are not described in the main analysis herein.
Manuscripts were deemed to be of particular interest
(marked with an ‘X’) if they devote a significant discus-
sion of ethics in relation to allergy (rather than limit
discussion of ethical issues to a paragraph or only a
short section heading within the manuscript, or if eth-
ical issues are delegated as a distinct topic for analysis
such that ethical issues are not framed particularly
within the context of allergy).
In order to provide a simple comparison in the
amount of ethics research available for chronic diseases
other than allergy, the parameters of the literature
search were repeated for obesity. However, this literature
review was limited to the term ‘obesity’ (e.g., using
search terms ‘obesity ethics’, ‘obesity moral’, etc.), and did
not include searches employing terms for common co-
morbid conditions (e.g., metabolic disorder, diabetes).Results and analysis: the paucity of academic articles
concerning ethics and allergy
The amount of ethical reflection and research in aller-
gology is arguably limited at best (Table 2). The results
from the exhaustive literature search identified fewer
than 50 academic articles on the subject of ethics and
allergy, which spans 31 years of academic research
(1980–2012). The majority of articles retrieved from
this search (approximately 90%) have been published
within the last ten years alone (2002–2012). Of these
50 articles, fewer than 35 contain a significant analysis
of ethical issues in allergology (i.e., articles in which the
authors provide a detailed description of ethical issues
concerning allergy, rather than merely mention ethical
issues within a paragraph or brief section within the
manuscript; in Table 2, these articles are indentified
with an ‘X’). This publication history indicates that
Table 2 Summary of results from the literature search for









2011 Kreger et al. X [38]
Behrmann X [39]
Master et al. X [40]
2010 Landrigan et al. [41]
Behrmann X [42]
Behrmann X [2]
Ellwood et al. X [43]
2009 Engler et al. X [44]
Brody et al. X [45]
2008 Park, Grayson X [46]
Craner X [47]
2007 Scherer et al. X [48]
Canonica [49]
Wise X [50]




Brody et al. X [53]




Brody et al. X [56]
Roberts [57]
Scherer et al. X [58]
Resnik et al. X [59]
Onder X [60]
2004 Rous, Hunt X [61]
Sutherland [62]
Dolen [63]
Coffey et al. X [64]
Annett et al. X [65]
Brown et al. X [66]
2003 Brown et al. X [67]
Midulla [68]
Brody et al. X [69]
2002 Miller, Shorr X [70]
Miller, Shorr X [71]
2001 Payne et al. [72]
Holley et al. [73]
2000 Holt, Sly [74]
1996 Storrs [75]
1995 Harth, Thong X [76]
Feingold [77]
Gibson et al. [78]
Table 2 Summary of results from the literature search for
ethical analysis in allergy (Continued)
1994 Holt [79]
1990 Olivier X [80]
French
articles
2009 Piette, Demoly X [81]
2001 Duguet et al. [82]
1999 Del Volgo [83]
1996 Lacronique [84]
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are exceptionally recent and not representative of a sus-
tained and long-term effort to advance knowledge in
this interdisciplinary domain of study; that is to say,
ethical concerns do not appear to ‘be on the radar’ of
the international allergology community.
In addition to the limited number of publications on
the subject, ethical analysis in allergology has, to date,
focussed discussion towards a select few domains of par-
ticular interest. Of the less than 35 articles which do de-
vote significant ethical analysis to issues in allergology,
approximately 70% of these articles target ethical issues
within research contexts. Of these articles concerning
research ethics, the vast majority (nearly 75%) concern
research on asthma. Only 8 articles identified in this lit-
erature search conduct a significant ethical analysis on
issues pertaining to public health and health policy in
allergology. No books devoting chapters to ethical issues
in allergy treatment or the distribution of atopic morbid-
ities were found. The small collection of articles identi-
fied appear somewhat insular with their findings, where
many articles remain separate from the others in terms
of subject for ethical scrutiny. In other words, there are
few links between these research publications, such that
the information provided in earlier publications rarely
‘cross-fertilises’, ‘builds upon’, or cites subsequent works
concerning ethics and allergy.
To date, ethical issues at the centre of analysis in aller-
gology have an appreciable degree of variety, though many
share a common theme. For example, and as mentioned
above, a significant proportion of ethical scrutiny has fo-
cused on asthma research. Several publications identify
particular ethical issues related to human subjects specific-
ally [40,43,50,52,59,76], where many ethical analyses iden-
tify particular risks, benefits, and concerns of asthma
investigations involving adolescent and other paediatric
populations [45,46,48,53,55,56,58,64,65,69]. Additionally,
allergy professionals have questioned whether it is ap-
propriate to uphold the status quo in clinical trials for
novel asthma medications. Concerns within this context
primarily question if placebo controls in such trials are ab-
solutely necessary or appropriate, since administering pla-
cebos while withholding conventional treatment regimens
may expose human subjects with respiratory ailments to
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have raised significant concerns concerning the quality and
safety of clinical trials in allergology which, in addition to
questions about duties to protect research subjects, aim
criticism towards conflicts of interest in industry sponsored
clinical trials and the publication of biased research find-
ings [47,51,70]. Moving beyond publications related to re-
spiratory disease, one article questions whether it remains
appropriate to use human subjects for potency assessments
needed for the standardisation of allergenic extracts used
in immunotherapy [39].
Unlike the situation for research ethics, ethical scru-
tiny within clinical contexts appears limited and focuses
attention towards a less diverse range of issues. One art-
icle written in French provides guidance on the appro-
priate use of allergy diagnostic tests amongst the
population of pregnant women [81]. Certain diagnostic
strategies (e.g., provocation tests) carry elevated risks of
harm for pregnant women and their foetus; thus, admin-
istering such tests to this category of patients is deemed
unethical and entirely contraindicated. A second article
centres attention on the needs of clinicians (mainly oc-
cupational health experts), that are challenged with diag-
nosing occupational allergy and asthma accurately [80].
This article provides valuable guidance on how to avoid
conflicts and tensions between employees with apparent
occupational illnesses and companies wishing to avoid li-
ability. A final article of clinical focus raises concern over
the growing number of patients purchasing allergy and
asthma treatments that fall under the heading of ‘com-
plementary and alternative medicine’ (CAM) [44]. Pri-
mary ethical issues relate to the lack of safety and
efficacy assessments for these alternative therapeutic
regimens, where the article subsequently provides guid-
ance to physicians on how best to inform patients of
possibly ineffective treatments.
Similar to clinical contexts, ethical analysis in relation
to health policy and public health is very limited. Two
articles identify key moral issues and ethical guidelines
for childhood food allergy policies at schools and child
care facilities [2,61]. In terms of public health contexts,
core concepts of justice are primary issues of recent
scholarship. Three articles present notions of environ-
mental justice to critique the concentration of atmos-
pheric pollutants in impoverished neighbourhoods,
which in turn impose a disproportionate burden of
asthma morbidity on vulnerable populations [38,66,67].
And lastly, one article presents a public health policy as-
sessment framework based on core principles of social
justice [42]. This framework aims to provide guidance in
the prioritisation of interventions to reduce environmen-
tal allergens and asthma triggers.
In addition to the publications presented in the main
analysis above, this literature search also retrieved 29very short publications comprising correspondence
pieces, letters to the editor, editorials, and commentaries
(Table 1). For the majority of these publications, the dis-
cussion devoted towards ethical issues is for the most
part exceptionally brief and specific, and thus, it is
expected that these publications are of little interest to a
broad audience and do not significantly advance scholar-
ship concerning ethics in allergology (indeed, this is typ-
ically not the goal of such publications). However, a
selection of these short works are notable exceptions
(Table 1; publications of interest). For example, the publi-
cations by Kling [10,11,19] provide concise overviews of
core concepts in medical ethics, such as conflict of inter-
est in research, and indicate why these issues are pertin-
ent to investigations in allergy. These publications
provide a readily tangible knowledge transfer activity use-
ful in informing clinicians and researchers about the
basics of ethical issues in allergology. A collection of edi-
torials are also of interest in that they aim to stimulate
further debate on important issues or direct greater at-
tention towards largely overlooked topics that merit fur-
ther ethical scrutiny. These topics include apparent
scientific misconduct in the development of best practice
guidelines for allergy treatment [29], debates over the
(in)accessibility and utility of adrenaline for patients at
risk for anaphylaxis [17], and the need to conduct further
clinical trials that focus on paediatric populations in
order to assess accurately the safety and efficacy of novel
asthma treatments [15].
A comparison with ethics scholarship concerning obesity
Though the results from this literature review indicate
ethical analysis in allergology appears quite limited,
these results are not necessarily indicative of a true de-
ficiency of knowledge or a lack of initiative in this area
of study. It could be argued that ethical analysis in
health science and policy (i.e., different from clinical or
research ethics) is a relatively new domain of scholar-
ship; thus, it is unsurprising that investigations con-
cerning ethical issues pertaining to the particular
disease of allergy are still in their infancy. Indeed, re-
search in biomedical ethics only began to develop
prominence in the 1960’s, and the sub-specialization of
public health ethics gained notoriety at the beginning
of the 1990’s [85] p. vi-viii. To address this possibility,
the parameters of the literature search were replicated
for the chronic disease of obesity in order to enable a
simple comparison between the amount of ethics
scholarship in relation to both diseases. (For a full list-
ing of publications cited in the following paragraph
[references denoted by ‘s’], see Additional file 1: the cor-
responding supplemental file for this article.)
Obesity is a useful disease for comparison due to its simi-
larities with allergy. Namely, both are chronic diseases that
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population incidence (>25% of populations in developed
countries), and both have recently exploded into epidemic
proportions that pose a significant challenge to public
health [s1-3]. From this less expansive literature search,
over 60 manuscripts pertaining to obesity and ethics were
identified, and accumulatively represent several hundreds
of pages of published material on the subject (data not
shown). Between 2007 and 2010, alone, 23 research articles
were published on ethics and obesity [s4-26]. Moreover,
unlike allergy where retrieved manuscripts were exclusive
to academic articles, analysis of ethical issues related to
obesity has been the focus of a book [s27] and the subject
of several book sections [s28-35]. Comparing obesity to al-
lergy, a reasonable conclusion derived from both literature
searches is that ethical analysis concerning allergy is very
limited and at an embryonic stage of academic develop-
ment. Arguments that ethics in health policy and public
health is too new a field of study for there to be extensive
application when analysing recent epidemics of disease are
not supported by these findings. Instead, the wealth of
scholarship available for ethics and obesity should serve as
inspiration concerning the future potential for ethics in
allergology. Overall, the paucity of ethical scrutiny for al-
lergy likely stems from other factors, such as lack of aware-
ness, interest, or capacities to engage in interdisciplinary
research that integrates ethical reflection with allergy re-
search and clinical practice [86]. The following Discussion
section will attempt to address these potential inhibitors to
an applied bioethics in allergology; but first, inherent lim-
itations of this analysis require a brief mention [86].
Limitations
The analysis above has notable limitations in terms of
the ethics content analysis of manuscripts identified in
this review. Having been assessed by the sole author of
this article, decisions concerning whether a manuscript
is ‘of particular interest’ is not representative of a rigor-
ous content analysis, but rather one expert’s opinion.
Thus, a degree of disaccord in these opinions is possible.
With that said, the classification of manuscripts based
on ethics content provided herein serves to provide a
basic assessment of the extent of ethical analysis of a
given publication. This ‘ethics content assessment’ aims
to solely aid readers in identifying publications that may
be of particular interest for future reference.
Discussion: adding ethics to the arsenal begins with
greater awareness
The provision of a broad argument supporting the need
for, and utility in, applying ethical principles to aid
decision-making capacities in biomedical and health con-
texts is not necessary for this article. For one, the vast
majority of clinicians and researchers – including thosespecialising in allergology – are probably already well fa-
miliar with basic principles of clinical and research ethics
that are now a mandatory component of most medical
training curricula and that regulate practice in scientific
research. The groundbreaking work by Beauchamp and
Childress [87], Principles of Biomedical Ethics is likely fa-
miliar since it has been incorporated into numerous best
practice medical guidelines. Without question, attending
to principles of autonomy, beneficence, non-maleficence,
and justice support good clinical practice and patient
care. In terms of research, most health scientists will be
familiar with the need to submit research proposals for
institutional ethics review, and core principles for the
protection of human subjects in research are essential
elements of international laws governing human experi-
mentation [88]. Furthermore, a recent wave of prominent
ELSI scholarship has likely gained wide recognition
amongst clinicians and researchers. Notable examples
include ethical guidelines in health administration and
the structuring of healthcare facilities [89], ethical cri-
tiques of the marketing of pharmaceuticals [90], and
the identification of key sources of conflicts of interest
that may compromise the quality of continuing med-
ical education [91]. Many of the core concepts, ethical
concerns, and debates advanced from such scholarship
are general enough that they impinge on, or are dir-
ectly pertinent to, allergy and related research. The
main point made here is that though targeted ethical
analysis in allergology is limited, it is important to
note that general ethical issues of clinical practice, re-
search ethics, health policy or scientific conduct are
applicable to all fields of health, including allergology.
Ethical issues unique to allergology that exemplify
promising areas of future research
While the above safeguards and broad ELSI scholar-
ship are well established in legislation, in professional
codes of ethics, and in medical practice guidelines, this
general knowledge base is not all-encompassing. There
are circumstances unique to allergology that require
greater awareness, scrutiny, and debate in order to
‘fine-tune’ the decision-making capacities of clinicians
and researchers. The following discussion will present
three examples to exemplify ethical issues of particular
significance to allergology, where these examples also
serve to identify three specific areas in allergy research
that merit future ethical analysis.
Consider the observation that visible minority patients
in the United States, such as African Americans, are less
likely to receive asthma treatment according to best
practice guidelines and are less likely to receive adequate
education concerning how to properly administer their
asthma medication [92]. These inequalities in treatment
provision do not necessarily arise because of endemic
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stem from patient characteristics such as socioeconomic
status [9], where patients possessing a higher education
level are more inclined to ask their physician necessary
questions concerning their treatment [93]. Regardless,
clinical allergists must be aware of the potential for inad-
vertent bias and thus strive to uphold principles of just-
ice in the provision of appropriate information and
asthma treatments to all patients. Future research should
assess means to minimize unjust inequalities in the
provision of asthma treatments and identify strategies to
avoid inadvertent biases that may arise when attending
to the needs of vulnerable patient populations.
Another example pertains to research, where emerging
clinical trials show promise in the development of im-
munotherapy for food sensitivities [94]. The expected
success of these trials will encourage further develop-
ment of additional food allergen vaccines and novel
treatment modalities. Yet, how ought future clinical
trials be constructed to investigate these novel drugs and
treatments, and what population(s) ought to compose
the primary study group? Since food allergy and asso-
ciated risks of anaphylaxis disproportionately afflicts
children [95,96], ought trials focus on establishing ap-
propriate dosing schemes for this population? While
children will stand to benefit most from clinical develop-
ments from these trials, including this vulnerable popu-
lation in research is typically discouraged and often
encounters significant ethical challenges (e.g., informed
consent with young children is often impossible) [55,97].
The allergy research community will need to debate
these ethical issues. At the very least, such ethical reflec-
tion will help avoid possible challenges concerning
innovation in immunotherapy and assist in securing
public, academic, and political support for these much
needed research endeavours.
As a final example, consider the link between techno-
logical innovation, the commercialization of novel ther-
apies, and access to essential drugs. For many people
with allergies and related atopic disorders, uninhibited
access to therapeutic interventions is indispensable to
achieving an appreciable quality of life. It is therefore dis-
quieting that numerous social, legal, and political factors
limit access to essential therapies. Consider recent inno-
vations that enabled the transition to chlorofluorocarbon
(CFC)-free asthma inhalers. Ozone depleting CFCs were
banned in manufacturing except for the production of
essential products, such as metered dose inhalers of
drugs used in the treatment of chronic lung disease
[98,99]. The purpose for this exception, however, was to
allow time for research to uncover suitable replacements.
Indeed, the discovery of novel, non-aerosol administra-
tion techniques and the propellant hydofluoroalkane
(HFA) enabled a gradual phase-out of CFCs in asthmamedications [100-102]. But these cumulative innova-
tions have not been exclusively beneficial. The patent-
ing of these novel drug administration methods has
resulted in pharmaceutical companies regaining mon-
opoly rights in the production of once common, and
inexpensive, generic asthma drugs [103]. Such monop-
oly privileges restrict access and impose cost-barriers
[104,105] to medications that many impoverished
people require to live free of severe disability (elevated
costs of treatment are also a major factor in patient
non-compliance to therapy [106]).
Surely these turn of events were not the intended goals
of the academic researchers that contributed towards
developing these CFC-free drug varieties. Moreover, in-
advertent restrictions in access to essential drugs runs
counter to core values that the application of research
knowledge should serve to benefit society while avoiding
the potential for harm whenever possible. Now cognizant
of these contradictions in values, researchers ought to as-
sess whether there are more ethical strategies to transfer
research knowledge into clinical application. Such strat-
egies would likely uphold and be guided by principles of
benefit maximization, harm reduction, and justice in the
provision of treatment; indeed, the choices made by se-
nior investigators and directors of research institutions
can help determine the success of these laudable strat-
egies. For one, investigators and directors of research
institutes could re-evaluate conditions that define patents
on innovations developed through their efforts or at their
institutions. Recent policies concerning the patenting of
innovations discovered at the University of British
Columbia (Canada) is a notable example [107]. Known as
the Global Access Initiative, some university polices
mandate that patent rights are transferred to corpora-
tions under the condition that products commercialized
from patented technology will be available to populations
of the developing world. To enable such access, corpora-
tions must provide discount pricing of products destined
for developing world markets. Future investigations by
allergy researchers should consider devising similar pol-
icies concerning patenting and assess whether these
models will uphold their core values of maximizing ac-
cess to, and the benefits of, medical innovations made at
their institutes.
The above examples of ethical issues in allergology
demonstrate the need for specific ethical analysis in this
field of health science. At a more general level, these
examples also demonstrate three topics within allergol-
ogy that merit future research and debate amongst al-
lergy experts. Greater ethical scrutiny in allergology will
undoubtedly uncover numerous additional issues of
interest. The remaining segment of this article will now
discuss tentative strategies allergy specialists and re-
search directors could employ in order to advance
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tion. The following recommendations aim to be readily
straightforward and will focus on encouraging interdis-
ciplinary collaborations between allergologists and
experts in applied ethics. Lessons learned from the estab-
lishment of successful ELSI programmes for human gen-
etics and nanotechnology will serve as examples for how
research institutes and funding bodies can help promote
ethics scholarship within allergology at a broader level.
Building knowledge in ethics in allergology will require
interdisciplinary collaborations: Lessons from ELSI research
programmes
Merging the terms ‘ethics’ and ‘allergology’ is a straight-
forward indication that advancing scholarship in this hy-
brid domain will necessitate interdisciplinary research,
and thus collaborative initiatives are inevitable (e.g., the
combination of neuroscience and ethics to form the field
of neuroethics [108]). Undeniably, it would be an overly
demanding claim that specialists in allergy become
equally specialized in another, unrelated domain of
scholarship, that is applied ethics. The need for expertise
beyond a level of general awareness and interest con-
cerning ethical issues, however, is not essential [109].
This expertise is already available through specialists in
fields such as business ethics, bioethics or environmental
ethics. Having raised arguments for greater awareness
and interest in ethical analysis in the previous sections,
this section will now discuss issues pertaining to estab-
lishing capacities to promote cross-disciplinary investi-
gations in allergology.
With the realization of the complex aetiologies of most
pathologies that challenge public health, experts agree
that effective policy strategies for these diseases will re-
quire knowledge sharing between multiple disciplines in
health research [110,111]. A growing call for training in
health sciences to become more interdisciplinary and in-
clusive of academic disciplines outside of science are
also voiced as strategies to improve academic training of
new scientists and clinicians [112-114]. Overall, encour-
aging interdisciplinary research that integrates ethics and
allergology would be consonant with this more general
movement. Indeed, establishing greater ties between the
biomedical and applied ethics communities sounds sim-
ple enough, though it does require a sustained initiative
to bridge divides and build capacities that enable real
collaboration.
In practice, establishing the groundwork for interdis-
ciplinary research is not simple and many experts voice
the need for greater support to foster communication
and interactions across disciplines [86,110,112,115]. In
particular, numerous administrative, cultural, funding al-
location, and geographical factors favour research spe-
cialising in one discipline. However, there exist means tobreak down barriers to interdisciplinary research [110];
as noted by Robillard and colleagues [86], the establish-
ment of dedicated ethical, legal and social implications
(ELSI) programs, such as those fully integrated into gen-
etics and nanotechnology, provide models for reforms in
other domains in the biomedical sciences. These models
merit further discussion here.
From the start, leaders in the field of genetics under-
stood that the race to map the human genome would
require both the promotion of capacities in science
and technology as well as careful attention towards the
ethical, legal, and social issues that would arise from
revolutionary understanding of human genetics [4].
Such foresight motivated the National Human Genome
Research Institute and the Department of Energy of
the United States government to establish in 1990 a
dedicated ELSI research programme for the Human
Genome Project (HGP). This programme allocated
over $30 million in research and education grants to
fund ELSI scholarship in human genetics. Integral to
the ELSI programme was the establishment of a net-
work of leading experts in ELSI scholarship (the ELSI
Working Group). This network facilitated discussion
and collaboration between scientists and ELSI scholars,
which in turn served to promote knowledge transfer
between research bodies and facilitate the development
of policy recommendations regarding the regulation of
novel genetic technologies. The establishment of the
ELSI programme for the HGP has since created a
‘snowball effect’. Similar ELSI programmes have been
replicated in additional domains of science and tech-
nology, as exemplified by the recent establishment of
an ELSI division within the National Nanotechnology
Program in the United States [116]. Similar to the
HGP, funding of nanotechnology research includes
grants dedicated specifically for investigations concern-
ing the broader ethical and societal concerns that may
arise from nanotechnology. Such macro-level pro-
grammes that promote ELSI research in health have
set precedence, one that could be replicated for allergy
and related disciplines. Indeed, similar initiatives now
exist, one example being a division of the Canadian
Network Centres of Excellence, AllerGen [117]. This
research network provides funding support and net-
working opportunities for interdisciplinary training and
research in allergy, where one its three specific goals is
to advance knowledge in the domain of “Public Health,
Ethics, Policy and Society” [117]. The funding and net-
work opportunities provided by AllerGen represents a
step forward in the promotion of research initiatives
that target the ethical, legal, and social implications
within allergology.
The take-home message here is that individual clini-
cians and researchers do not have the sole responsibility
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linary research. Rather, research institutes and depart-
ments in allergology have an equally important
responsibility to establish programmes and administra-
tive infrastructure that will favour fruitful collaborations
with other domains, including applied ethics. Despite ad-
ministrative, cultural, and geographical barriers to inter-
disciplinary research, members of the allergology
community do not need to wait for broad administrative
changes in their organisations and research institutes be-
fore initiating interactions with specialists in applied eth-
ics. For one, most allergy specialists will likely have had
some association and familiarity with ethicists in their
place of work through evaluations of research protocols
by institutional review boards, or ethics consultations
within clinical contexts. The value of this established
professional network should not be underestimated and
should be seen as an opportunity. Merely engaging in
conversations with these colleagues – outside contexts of
evaluating research proposals or participating in ethical
consults for particular dilemmas – would be a simple
means to exchange ideas, and initiate future collabora-
tions and shared learning opportunities.
Conclusion
The paucity of ethical scrutiny in allergology described
in this article does not aim to denote solely a weakness
in this particular field of biomedical science. Rather, this
analysis aims to advance the argument that fostering the
development of applied ethics in allergology would en-
able many strengths and opportunities in allergy research
and in the optimal design of treatment and prevention
efforts. However, the fact that this literature search
retrieved fewer than 35 significant articles on ethics and
allergy signifies that much work remains to be done.
The rapid development of bioethics scholarship over the
past decade in relation to diseases like obesity, as well as
the recent development of ELSI research programmes in
several domains of science and technology, should serve
as inspiration of the potential that lies ahead for the
allergology community.
The growing awareness [6,8,85,118] that initiatives in
public health, decisions in health policy, and the emer-
gence of new technologies are laden with ethical dilem-
mas and political tensions signifies that decision-makers
in health would benefit from enhanced skills in applied
ethics. A greater awareness and sensitivity towards the
broader ethical, social, and political factors in health re-
search would also be of benefit for clinicians and inves-
tigators, including those specialising in allergy. At the
very least, having the ability to identify and verbalize
ethical issues in allergy would prove beneficial when
members of the allergology community are called forth
to provide their expert opinion concerning future policyinitiatives and strategies to quell the growth of this
chronic illness. In the absence of ethical reflection, one
must question whether decision-makers in health are
employing all the tools necessary to design optimal
treatment and prevention strategies. Furthermore, a lack
of academic publications that outline ethical issues that
are specific to allergy raise questions as to whether policy
makers are cognizant of important ethical tensions that
affect clinical practice and abilities to transfer research
knowledge into effective health interventions. Thus, the
current paucity of academic work in ethics in allergology
signifies that future imperatives in allergology should in-
clude greater collaborative efforts with members of the
applied ethics community in order to advance knowledge
in this largely overlooked domain of inquiry.
On a positive note, the seeming divide between ethics
and allergy research and clinical practice appears to be
on the cusp of change. In 2001, The European Acad-
emy of Allergy and Clinical Immunology (EAACI)
called attention to major areas in clinical and research
ethics that merited future intervention [19], and recom-
mended the establishment of a European Committee on
Ethics in Allergology (ECEA). And recall once again
that the Canadian research network, AllerGen, allocates
specific funding to support interdisciplinary training in
ELSI and public health research for allergy [117]. It is
unfortunate that these capacity building efforts in eth-
ics and allergology appear to have not yet reached
their full potential; this author did not find evidence
(e.g., a webpage) that the ECEA has been established,
and the exhaustive literature search retrieved only one
article where the authors were affiliated with AllerGen
[40]. Regardless, the positive position concerning ethics
scholarship put forth by these prominent organizations
indicates, at the very least, a nascent recognition of
the need for greater knowledge in this largely over-
looked area of allergology.
One can hope that the preliminary efforts towards cap-
acity building in interdisciplinary research made by these
prominent allergy organizations will provide impetus for
others to follow suit. This article aims to contribute to
this process by encouraging greater awareness of the un-
tapped ethical resources that await their application to-
wards addressing key dilemmas in allergology. Once
awareness builds, it is only a matter of time before the
current foundation of ethical analysis concerning allergy
will grow into a diverse body of knowledge and expertise.
This is not a question of if, but when; the future success
in developing effective policies and public health inter-
ventions for the epidemic of allergic disease depend on it.
Endnotes
a For this article, the following definitions for ‘ethics’
and ‘ethical analysis’ apply. Ethics is a branch of moral
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decision-making contexts, as well as the evaluation of
norms of conduct. Ethical reflection thus aims to define:
1) right versus wrong conduct; and, 2) distinctions that
delimit ‘bad’ versus ‘good’ versus ‘best’ choices. Ethical
principles and theories (e.g., uphold justice, do no harm)
attempt to justify and identify appropriate norms of con-
duct [87] p.2. Moving beyond abstract theories of moral
philosophy, the application of ethical principles as guides
in real-world decision-making contexts are the mainstay
of ‘applied ethics’ scholarship, common fields of applied
ethics being, for example, business ethics or bioethics.
‘Ethical analysis’ comprises a diversity of research meth-
odologies depending on the subject being investigated,
ranging from empirical studies to theoretical debates.
For example, ‘descriptive ethics’ investigates how mem-
bers of a group currently reason and act when faced
with a moral dilemma. Such investigations commonly
employ scientific methods in anthropology or qualitative
analysis of narratives (e.g., ‘do terminally ill patients con-
sider euthanasia to be justified?’). Theoretical investiga-
tions typically aim to provide guidance and frameworks
to guide the decision-making capacities of decision-
makers (e.g., what ought one do in this particular cir-
cumstance?), or identify foreseeable conflicts that may
arise from a given policy proposal. To expand, a policy
proposal may centre on devising means to avoid expos-
ure to allergens in schools by, for example, implement-
ing a ban on peanuts. An ethical analysis of this policy,
framed by the principle of ‘the fair distribution of bene-
fits and burdens’, would raise questions of weather this
ban may: 1) place an excessive burden on children that
commonly consume peanuts; and thus, 2) whether
school officials have a duty to minimize this burden by
offering suitable meal replacements for children affected
by a peanut ban (see ref: [2]).
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